FMR LLC and Abigail P. Johnson filed an amended beneficial ownership statement with the SEC on November 4, 2026, disclosing a combined position of 970,920 shares of Edgewise Therapeutics Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC and Abigail P. Johnson each reported beneficial ownership of 970,920.00 shares of Edgewise Therapeutics Inc. common stock.
  • Percent of class: The 970,920.00 shares represent 0.9% of Edgewise Therapeutics' outstanding common stock, according to the filing.
  • Sole voting power for FMR LLC: FMR LLC reported sole voting power over 970,340.50 shares, with zero shared voting power.
  • Sole dispositive power: FMR LLC reported sole dispositive power over 970,920.00 shares; Abigail P. Johnson separately reported sole dispositive power over the same 970,920.00 shares.
  • Triggering event date: The event requiring this filing occurred on September 30, 2026, per the statement.
  • Filing entity classification: FMR LLC is identified as a parent holding company (type "HC") organized in Delaware; Abigail P. Johnson is identified as an individual (type "IN") of United States citizenship.

FMR LLC Discloses Sub-5% Position in Boulder-Based Clinical-Stage Biotech

According to the amended filing, FMR LLC, headquartered at 245 Summer Street, Boston, Massachusetts 02210, reported aggregate beneficial ownership of 970,920.00 shares of common stock in Edgewise Therapeutics Inc. (NASDAQ:EWTX), a clinical-stage biopharmaceutical company based at 1715 38th St, Boulder, Colorado 80301. The filing is designated Amendment No. 1, indicating it updates a prior statement. The CUSIP number for the common stock is listed as 28036F105.

The filing notes that one or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Edgewise Therapeutics common stock, though no single other person's interest exceeds five percent of the total outstanding shares. FMR LLC, acting as a parent holding company, identified a relevant subsidiary in Exhibit 99 attached to the filing. Abigail P. Johnson, who reported zero sole or shared voting power, is listed alongside FMR LLC as reporting the same 970,920.00 shares under sole dispositive power.

Both FMR LLC and Abigail P. Johnson certified, through authorized signatory Stephanie J. Brown, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The statement was signed on November 4, 2026, with the triggering event date of September 30, 2026.

What Was Disclosed

FMR LLC and Abigail P. Johnson filed an amended beneficial ownership statement covering 970,920.00 shares, or 0.9%, of Edgewise Therapeutics Inc. common stock, with the triggering event dated September 30, 2026, and the statement signed November 4, 2026.